
Use of Blautia probiotic strain to treat the flu and prevent secondary bacterial infections



Description

The team has shown that this bacteria lowers the number of secondary bacterial infections of the lungs seen in influenza



Type of expected transfer

Research collaboration with licence option

Advantages

Zero harmful inflammatory actions, Very large genome 3400 bp, Bacterial genus highly abundant in the microbiome of healthy adults, Tests in a preclinical influenza model suggest a stimulating effect on the immune system and fight against secondary infections by S pneumoniae

Possible applications

The results suggest that this strain can stimulate digestive and pulmonary immune defenses by producing large amounts of acetate

Key words

KEY WORDS: acetate, anaerobic, oxygen free, Blautia , dysbiosis , influenza, immune system, probiotics



Development level

This strain, isolated from human stool, can produce up to 70 mM of acetate in vitro. This ability to produce such a large amount can prevent the proliferation of opportunistic species

Laboratories: Micalis

Researchers: Muriel Thomas

Contact:

Austin SHOWALTER Tel 33 646 545 215 - Email austin.showalter@inrae.fr

Date: 21-10-2020

Head Office:28, rue du Dr. Finlay - 75015 Paris - Telephone: +33 1 42 75 95 00 - Fax: +33 1 45 77 6390 A simplified joint-stock company with a capital of 1 920 000€ - RCS PARIS B 433 960 762 - SIRET: 433 960 762 00030 - APE 6630Z - TVA FR 96 433 960 762

INRAE Transfer Technology offers : www.inra-transfert.fr